The Use of Sulfanilamide in the Treatment of Chronic Ulcerative Colitis

Author and Disclosure Information


In the consideration of a new form of therapy for chronic ulcerative colitis it is well known that one year’s experience and its use in eleven cases does not justify a final appraisal. The natural remissions of symptoms characteristic of this disease have been responsible for inaccurate appraisal of treatment in the past, unless evaluated in terms of repeated examinations over years of time and by independent investigators. On the other hand, this is an unusually serious disease and when the initial response to a new form of treatment is unusually favorable, we believe others should have the advantage of this experience before awaiting final appraisal.

In our experience, cultures made from rectal scrapings and stools have so commonly shown the presence of various strains of streptococci that a therapeutic trial with sulfanilamide seemed logical.

In eight of our eleven cases we found the initial response to sulfanilamide therapy more satisfactory in a shorter period of time than has been our experience with other forms of medical treatment. Since the progress proctoscopic examinations have revealed unexpected improvement if not normal findings, without scar formation, we believe this group of patients must have had unusually superficial involvement of the wall of the rectum and colon. Heretofore, although the patient had had a complete remission of symptoms, if a proctoscopic examination were done during the remission, the findings were unfortunately too often the same as those visualized at the time of the acute exacerbation of the disease.

The “regional” or so-called “right-sided”. . .



Next Article: